Bret A. Witter, MD, FACC, FACP

Dr. Bret A. Witter joined Los Alamitos Cardiovascular in 2003 as a partner. Dr. Witter is board certified in Echocardiography, Cardiovascular Disease and Internal Medicine. Since 1996, Dr. Witter has been an Assistant Clinical Professor at the David Geffen School of Medicine, UCLA.

Dr. Brett A. WitterI enjoy meeting new people and listening to their medical issues. Together we find a plan that meets their specific needs...

On Medicine
It is still fun. Despite its demands, I cannot imagine working in any other profession.

On Los Alamitos Cardiovascular
I moved my practice here in 2003. It has been my pleasure to work, not only with the doctors in this group, but with the entire office staff.

On My Specialty
It has been said that keeping up with the advances in cardiology is like drinking from a fire hydrant. I strive to keep pace with all the exciting advances in cardiology and apply them when appropriate.

Dr. Bret A. Witter's Curriculum Vitae

Printable Version View Printable CV
Specialties: Cardiovascular Diseases and Echocardiography
Board Certifications:
  • Certified Echocardiography
    National Board of Echocardiography
  • Certified in Cardiovascular Disease
    American Board of Internal Medicine
    November 1993 (Recertifications: 2003 and 2013)
  • Certified in Internal Medicine
    American Board of Internal Medicine
    1990 (Recertifications: 2000 and 2009)
  • FLEX (Federal Licensing Examination)
    Part 1: 1985 | Part 2: 1986
  • National Boards (Taken Individually)
    1984 – 1987
  • NASPE Testamur (Exam)
    North American Society of Pacing and Electrophysiology
Current Hospital Appointments:
  • Los Alamitos Medical Center
    3751 Katella Avenue
    Los Alamitos, California 90720

  • Long Beach Memorial Medical Center
    2801 Atlantic Avenue
    Long Beach, California 90806
Hospital Activities: Los Alamitos Medical Center
  • Chairman, Pharmacy and Therapeutics, 2008 – 2014
St. Mary Medical Center
  • Vice Chief of Medicine, 2002 – 2003
  • Medical Director of Cardiopulmonary Unit, 2003
  • Pharmacy and Therapeutics, 2001 – 2002
  • Cardiac Catheterization/Cardiac Surgery Committee, 1996 – 2003
  • Cardiac Catheterization/Cardiac Surgery Committee,1996 – 2000
  • CCU/ICU Committee, 1994
MemorialCare Health System
Community Hospital Long Beach
  • Chairman, Cardiac Advisory Board, 1996 – 1998
Professional Societies:
  • American College of Physicians (FACP)
    Fellow: February 2002
  • American College of Cardiology (FACC)
    Fellow: May 1995
  • Los Angeles County Medical Association
    Member: 1995 – Present
  • American College of Cardiology
    Member: 1990 – Present
  • American College of Physicians
    Member: 1987 – Present
Academic Appointments: Assistant Clinical Professor
David Geffen School of Medicine
University of California, Los Angeles (UCLA)
1996 – Present
Work History:
  • Los Alamitos Cardiovascular
    Los Alamitos, California
    October 1993 – Present

  • Cardiovascular Associates
    Long Beach, California
    July 1993 – October 1993
  • Cardiology Conference
    St. Mary Medical Center Long Beach
    2007 – Present
  • ICU Morning Report
    St. Mary Medical Center Long Beach
    1993 – 2003, 2007 – 2009
  • CCU/Cardiology Rounds
    St. Mary Medical Center Long Beach
    1993 – 2003
Professional Recognition:
  • Special Recognition for Teaching Excellence
    St. Mary Medical Center  Long Beach
    2003 – 2004
  • Outstanding Teaching Physician
    St. Mary Medical Center Long Beach
    2000 – 2001
  • Outstanding Teaching Physician
    St. Mary Medical Center Long Beach
    1993 – 1994
Intramural Presentations:
  • "Differentiation of Cardiac and non Cardiac chest pain."
    CARDIOLOGY 2000 symposium at Long Beach, California Hyatt,
    May 13, 2000.
  • "Transesophageal Echocardiography in the Critical care Setting." CRITICAL CARE TRIAD, St. Mary Medical Center Long Beach, January 19, 1995.
  • Witter BA, Decristofaro D. "Muscle Bands, Tendons and Trabeculations." (Letter) Am J. Cardiol. 1992; 71:499 – 500.

  • Cardiovascular Diseases Fellowship
    St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
    Long Beach, California
    July 1990 – June 1993

  • Internal Medicine Residency
    St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
    Long Beach, California
    July 1988 – June 1990

  • Internal Medicine Internship
    St. Mary Medical Center Long Beach /Affiliated with UCLA School of Medicine
    Long Beach, California
    July 1987 –  June 1988

  • Medical Education
    Baylor College of Medicine

    Houston, Texas
    August 1983 – June 1987

  • Undergraduate Education
    Biological Sciences
    University of California, Irvine (UCI)

    Irvine, California
    September 1979 – June 1983

Educational Honors and Awards:
  • Phi Beta Kappa
    Magna Cum Laude
    University of California, Irvine 1983

Research Experience:
  • GALACTIC-HF: Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction.
    Sub-Investigator | 2017
    Sponsor: Amgen

  • PROVE-HF: A 52 Week, Open Label Evaluation of the Effects of Sacubitril/Valsartan (LCZ696) Therapy on Biomarkers, Myocardial Remodeling and Patient-reported Outcomes in Heart Failure With Reduced Left Ventricular Ejection Fraction.
    Sub-Investigator | 2017
    Sponsor: Novartis

  • Barostim Therapy for Heart Failure (BeAT-HF): The Barostim Neo - Baroreflex Activation Therapy for Heart Failure is a prospective, randomized trial in subjects with reduced ejection fraction heart failure.
    Sub-Investigator | 2016 – Present
    Sponsor: CVRx, Inc.

  • MLHFQ Study: Evaluate and establish content validity of the Minnesota Living with Heart Failure Questionnaire (MLHFQ) in patients with Symptomatic Hypertrophic Cardiomyopathy.
    Sub-Investigator | 2016
    Sponsor: Gilead/ICON

  • THEMIS- A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus (THEMIS): A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in Diabetes Mellitus Patients Intervention Study).
    Sub-Investigator | 2015 – Present
    Sponsor: AstraZeneca
    NCT01991795 |

  • Retrospective Medical Records Review of Participants Interviewed for Study M-12347 (Concept Elicitation Focus Groups and Cognitive Interviews to Develop a New Patient Reported Outcome Instrument in Chronic Heart Failure).
    Sub-Investigator | 2015
    Sponsor: Amgen, Evidera

  • DECLARE-TIMI 58 Dapagliflozin Effect on CardiovascuLAR Events: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes.
    Sub-Investigator | 2013 – Present
    Sponsor: AstraZeneca
    NCT01730534 |

  • ODYSSEY EFC11570: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome
    Sub-Investigator | 2013 – Present
    Sponsor: Sanofi
    NCT01663402 |

  • SILVER-AMI Risk Stratification in Older Persons with Acute Myocardial Infarction.
    Sub-Investigator | 2013 – 2017
    Sponsor: Yale University School of Medicine/NIH
    NCT01755052 |

  • RivaroxAFL3003: An Open Label Study Exploring two treatment strategies in patients with Atrial Fibrillation who undergo Percutaneous Coronary Intervention.
    Sub-Investigator | 2013
    Sponsor:  Janssen Scientific Affairs/Johnson & Johnson

  • Phase III Trial to confirm the Anti-Anginal effect of T-89 in patients with Stable Angina.
    Sub-Investigator | 2013
    Sponsor: Tasly Pharmaceuticals
    NCT0169580 |

  • Cardiovascular Inflammation Reduction Trial (CIRT): Event Driven Trial of weekly Low-Dose Methotrexate in prevention of recurrent cardiovascular events among stable post myocardial infarction patients with Type II Diabetes or Metabolic Syndrome.
    Sub-Investigator | 2013 – Present
    Sponsor: Center for Cardiovascular Disease Prevention Brigham and Women’s Hospital/National Heart Lung and Blood Institute
    NCT01594333 |

  • User Comprehension Evaluation of a New Cleaning and Disinfection Procedure for the INRatio® 2 PT/INR Monitoring System (ADAPT) BSTE-0159.
    Sub-Investigator | 2012
    Sponsor: Alere San Diego

  • Mission® PT Coagulation Monitoring System Clinical Study.
    Principal Investigator | 2012
    Sponsor: ACON Laboratories, INC.

  • The "BRIDGE" Trial (1U01HL08675501A1): Bridging Anticoagulation in Patients Who Require Temporary Interruption of Warfarin Therapy for an Elective Invasive Procedure or Surgery.
    Sub-Investigator | 2012 – 2015
    Sponsor: National Institutes of Health (NIH)-National Heart, Lung and Blood Institute (NHLBI)
    NCT00786474 |

  • GLORIA-AF 1160.129: Global Registry on Long-Term Oral Anti-thrombotic Treatment in Patients with Atrial Fibrillation Phase II-III.
    Sub-Investigator | 2012 – Present
    Sponsor: Boehringer Ingelheim
    NCT01468701 |

  • BRADYCARE: Advanced Bradycardia Device Feature Utilization and Clinical Outcomes.
    Sub-Investigator | 2010 – 2012
    Sponsor: St. Jude Medical Center
    NCT01062126 |

  • The PROMISE Trial: PROspective Multicenter Imaging Study for Evaluation of Chest Pain.
    Sub-Investigator | 2010 – 2014
    Sponsor: National Heart, Lung, and Blood Institute (NHLBI)
    NCT01174550 |

  • ORBIT-AF I and II: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation.
    Sub-Investigator | 2010 – Present
    Sponsor: Janssen Scientific Affairs, LLC
    Collaborator: Duke Clinical Research
    NCT01165710 |
    NCT01701817 |

  • RATE: Registry of Atrial Tachyarrhythmia/Atrial Fibrillation (AT/AF) Episodes in the Cardiac Rhythm Management (CRM) Device Population.
    Principal Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00837798 |

  • FREEDOM: A Frequent Optimization Study the Quick Opt ™ Method.
    Sub-Investigator | 2008 – 2010
    Sponsor: St. Jude Medical Center
    NCT00418314 |

  • SAFE (Silent Atrial Fibrillation Detection with Stored EGMS).
    Sponsor: Guidant Corporation

  • ENGAGE: Phase III, randomized, double-blind, double-dummy, parallel group, multi-center, multi-national study for evaluation of efficacy and safety of DU-176b versus Warfarin in subjects with Atrial Fibrillation - Effective Anticoagulation with Xa next Generation in Atrial Fibrillation (ENGAGE - AF TIMI - 48).
    Sub-Investigator | 2009 – 2015
    Sponsor: Daiichi Sankyo Pharma Development
    NCT00781391 |

  • Fosiniopril Drug Study.
    Sub-Investigator | 1992
    Sponsor: Bristol- Myers Squibb Company

  • Supine Bike/Stress Echo (Unpublished).
    A.S. Abbasi, MD, FACC
    Long Beach, California.

  • Molecular Biology/ Immunology Cell Culture, electrophoresis techniques, 1978 – 1979. Gale Granger, PhD
    University of California, Irvine.
Foreign Language:

Medical Spanish